Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Combination of Oral PDE5-Inhibitor (Sildenafil) And Oral Prostacyclin Analogue (Beraphrost) Therapy for Increasing Quality of Life in Adults with Pulmonary Arterial Hypertension Related to Uncorrected Secundum Atrial Septal Defect

Heart Science Journal · Vol. 2 No. 4 (2021) · hlm. 20–24

DOI
10.21776/ub.hsj.2021.002.04.5
ISSN
2721-9984, 2721-9976
Terbit
2021-10-31
Penerbit
Universitas Brawijaya
Bahasa
en

Abstrak

Background: Sildenafil, an oral phosphodiesterase type-5 inhibitor, has vasodilatory effects through a cyclic guanosine 3,5-monophosphate–dependent mechanism, whereas beraprost, an oral prostacyclin analog, induces vasorelaxation through a cAMP-dependent mechanism.Objective: To investigate whether the combination of oral sildenafil and beraprost is superior to sildenafil alone in in adult patients with PAH related uncorrected secundum ASD.Method: Patients with secundum ASD who developed PAH divided into two group. Group A received oral sildenafil 3x40 mg and oral beraphrost 3x20mcg. Group B received oral sildenafil only 3x40 mg in a 12-week. Health-related quality of life (HRQoL) was recorded by patients using the Medical Outcomes Study 36-item short form (SF-36) questionnaires at baseline and after 12 of therapy. Therapy adherence was achieved through a series of phone calls and a four-weekly hospital visit. Every normal follow-up appointment included an examination of side effects and a dosage modification based on the clinical situation.Results: We didn’t found any significant of proportion different in Comorbid condition between groups. Compared with Group B, Group A had increased in physical functioning, Limitation to physical health, Energy fatigue, Pain, and health change (P=0.00, P=0.03, P=0.044, P=0.026, P=0.008, respectively).Conclusion: We suggest that combination between oral sildenafil therapy 40 mg three times per day and Beraphrost 20mcg two times per day significantly increase the HRQOL in PAH patients due to uncorrected secundum ASD.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 266 tautan kepenulisan bersama · 20 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • RSUD Prof. Dr. Saiful Anwar Malang
  • Sapienza University of Rome
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Cholid Tri TjahjonoUniversity of Brawijaya13
Anna Fuji RahimahUniversity of Brawijaya13
Mohammad Saifur RohmanUniversity of Brawijaya12
Indra PrasetyaUniversity of Brawijaya11
Ardian RizalUniversity of Brawijaya7
Novi KurnianingsihUniversity of Brawijaya7
Setyasih AnjarwaniUniversity of Brawijaya6
Valerinna YogibuanaAfiliasi tidak diketahui5
Budi SatrijoUniversity of Brawijaya5
Djanggan SargowoUniversity of Brawijaya4
Sasmojo WiditoUniversity of Brawijaya4
Wella KarolinaUniversity of Brawijaya3
Seprian WidasmaraUniversity of Brawijaya2
Zainal FathurohimUniversity of Brawijaya2
Valerinna Yogibuana Swastika PutriUniversity of Brawijaya2
Lukitasari Ayu Galuh ArdhiUniversity of Brawijaya2
Indra Jabbar AzizUniversity of Brawijaya2
Danti Utami SetyowatiRSUD Prof. Dr. Saiful Anwar Malang2
Putri Annisa KamilaUniversity of Brawijaya2
Yoga WaranugrahaUniversity of Brawijaya2
Ratih Kusuma WardaniAfiliasi tidak diketahui1
Renny SuwarniatyUniversity of Brawijaya1
Taufieq Ridlo MakhmudUniversity of Brawijaya1
Faris Wahyu NugrohoUniversity of Brawijaya1
Annisa Dallilatul HasanahUniversity of Brawijaya1
Bambang KusbandonoUniversity of Brawijaya1
Citra TarannitaUniversity of Brawijaya1
Djanggan SargowoAfiliasi tidak diketahui1
Jonny Karunia FajarUniversity of Brawijaya1
Aditha Satria MaulanaUniversity of Brawijaya1
Aris Munandar Zulkifli IsmailUniversity of Brawijaya1
Monika SitioUniversity of Brawijaya1
Ayu Asri Devi AdityawatiUniversity of Brawijaya1
Irma KameliaUniversity of Brawijaya1
Hendrawati HendrawatiUniversity of Brawijaya1
Salvatore Di SommaSapienza University of Rome1
Liemena Harold AdrianRSUD Prof. Dr. Saiful Anwar Malang1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://heartscience.ub.ac.id/index.php/heartscience/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">The Combination of Oral PDE5-Inhibitor (Sildenafil) And Oral Prostacyclin Analogue (Beraphrost) Therapy for Increasing Quality of Life in Adults with Pulmonary Arterial Hypertension Related to Uncorrected Secundum Atrial Septal Defect</dc:title>
	<dc:creator xml:lang="en">Martini, Heny</dc:creator>
	<dc:creator xml:lang="en">Fadlan, Muhammad Rizki</dc:creator>
	<dc:creator xml:lang="en">Nurudinulloh, Akhmad Isna</dc:creator>
	<dc:subject xml:lang="en">pulmonary hypertension</dc:subject>
	<dc:subject xml:lang="en">secundum ASD</dc:subject>
	<dc:subject xml:lang="en">quality of life</dc:subject>
	<dc:description xml:lang="en">Background : Sildenafil, an oral phosphodiesterase type-5 inhibitor, has vasodilatory effects through a cyclic guanosine 3,5-monophosphate–dependent mechanism, whereas beraprost, an oral prostacyclin analog, induces vasorelaxation through a cAMP-dependent mechanism.Objective : To investigate whether the combination of oral sildenafil and beraprost is superior to sildenafil alone in in adult patients with PAH related uncorrected secundum ASD.Method : Patients with secundum ASD who developed PAH divided into two group. Group A received oral sildenafil 3x40 mg and oral beraphrost 3x20mcg. Group B received oral sildenafil only 3x40 mg in a 12-week. Health-related quality of life (HRQoL) was recorded by patients using the Medical Outcomes Study 36-item short form (SF-36) questionnaires at baseline and after 12 of therapy. Therapy adherence was achieved through a series of phone calls and a four-weekly hospital visit. Every normal follow-up appointment included an examination of side effects and a dosage modification based on the clinical situation.Results : We didn’t found any significant of proportion different in Comorbid condition between groups. Compared with Group B, Group A had increased in physical functioning, Limitation to physical health, Energy fatigue, Pain, and health change (P=0.00, P=0.03, P=0.044, P=0.026, P=0.008, respectively).Conclusion : We suggest that combination between oral sildenafil therapy 40 mg three times per day and Beraphrost 20mcg two times per day significantly increase the HRQOL in PAH patients due to uncorrected secundum ASD.</dc:description>
	<dc:publisher xml:lang="en">Universitas Brawijaya</dc:publisher>
	<dc:date>2021-10-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://heartscience.ub.ac.id/index.php/heartscience/article/view/217</dc:identifier>
	<dc:identifier>10.21776/ub.hsj.2021.002.04.5</dc:identifier>
	<dc:source xml:lang="en">Heart Science Journal; Vol. 2 No. 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease; 20-24</dc:source>
	<dc:source>2721-9984</dc:source>
	<dc:source>2721-9976</dc:source>
	<dc:source>10.21776/ub.hsj.2021.002.04</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://heartscience.ub.ac.id/index.php/heartscience/article/view/217/276</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2021 Heny Martini, Muhammad Rizki Fadlan, Akhmad Isna Nurudinulloh</dc:rights>
</oai_dc:dc>